Osteoarthritis
This article was originally published in The Tan Sheet
Executive Summary
Novel blend of fatty acid esters (CMC) "may improve the quality of life in patients with [osteoarthritis]," poster presented at FASEB meeting by R.R. Barathur, ClinCyte, et al., states. Double-blind, placebo-controlled, 60-day study of 100 subjects found that after 30 days subjects taking a CMC capsule daily showed a reduction in the Lequesne's Disease Severity Index, identified by knee pain, stiffness and function. The CMC group also displayed "significant improvements in flat ground walking and traversing up and down stairs"
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning